All Alzheimer's articles – Page 2
-
BusinessSixth in a line of Alzheimer’s drugs fails in trials
Treatments designed to stop amyloid peptide formation all seem to cause cognitive impairment rather than prevent it
-
PodcastAmantadine
Katrina Krämer investigates how one of the smallest small molecule drugs around saved Jeanna Giese's life
-
ResearchAlzheimer’s linked to infection of the brain by gum disease bacterium
Drug firm is developing treatment to inhibit bacterial enzymes believed to be damaging important protein
-
ResearchScorpion venom peptide engineered to sting brain disorders
Structure used to escort nanoparticles across blood–brain barrier also resists protease degradation
-
FeatureUnderstanding Alzheimer’s
After hundreds of failed drug candidates, James Mitchell Crow asks if this is the last roll of the dice for the amyloid theory of Alzheimer’s disease
-
NewsBeetroot beats route to Alzheimer's
Betanin, the compound that gives beetroot it’s distinctive purple colour, may slow the process of protein misfolding that is linked to Alzheimer’s disease
-
BusinessDementia slips down pharma agenda
Pfizer, Shire, Acorda and Axovant rethink their neuroscience strategies
-
ResearchRoute to fiendishly complex marine molecule cut in half
Shortcut to promising natural product already in Alzheimer’s and HIV trials
-
NewsAlzheimer’s disease: have drug developers been on the wrong track?
Dementia drug developers urged to look beyond amyloid
-
PodcastAdamantane
Brian Clegg introduces a crystalline hydrocarbon that isn’t as tough as it sounds, but is the basis of a wide range of medicines
-
ResearchOverlooked hydrogen bond at heart of proteins
Weak interaction stabilises β-sheets and may help understand diseases such as Alzheimer’s
-
Business
Actavis plan to thwart generics blocked
Company prevented from withdrawing original formulation of Alzheimer’s drug to force patients onto extended release version and extend patent exclusivity
-
ResearchCoated nanoparticles show Alzheimer's promise
Gold nanoparticles functionalised with amino acid polymer inhibit the growth of amyloid fibres associated with neurodegenerative disease
-
Business
Alzheimer's drug flops in Phase III
Solanezumab from Eli Lilly missed the cognitive and functional primary endpoints of the trials
-
Business
Bapineuzunab dropped
Development for the Alzheimer’s treatment stopped after clinical tests
-
- Previous Page
- Page1
- Page2
- Next Page